Liraglutide antidiabetic drugs

victoza - liraglutide



Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - insulin secretagogues peptides (incretins) in all type of patients - antidiabetic drugs in patients inadequately controlled on monotherapy - antidiabetic drugs in patients with insufficient glycaemic control with bitherapy - antidiabetic drugs in Patients inadequately controlled on MET+SU therapy - antidiabetic drugs in patients inadequately controlled on metformin - glucose lowering for cardiovascular prevention in all type of patients - insulin secretagogues peptides (incretins) in obese individuals - antidiabetic drugs in patients inadequately controlled with insulin

LEADER, 2016liraglutideplacebo9340 (4668/4672) Exploratory NCT01179048
LEAD-3 mono 1.2mg (Garber), 2009liraglutide 1.2mgglimepiride499 (251/248) Confirmatory NCT00294723
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009liraglutide 1.2mgglimepiride (add on MET)485 (241/244) Confirmatory NCT00318461
LEAD-2 (Nauck) (1.2mg vs placebo), 2009liraglutide 1.2mgplacebo (add on MET)363 (241/122) NCT00318461
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU)343 (228/115) Confirmatory NCT00318422
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)355 (178/177) NCT00333151
LEAD-1 SU (1.2 vs rosiglitazone), 2009liraglutide 1.2mgrosiflitazoneNA
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptin444 (225/219) Confirmatory - NCT00700817
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SU464 (233/231) Confirmatory - NCT00518882
LEAD-3 mono 1.8mg (Garber), 2009liraglutide 1.8mgglimepiride495 (247/248) Confirmatory NCT00294723
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)486 (242/244) NCT00318461
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET)466 (232/234) Confirmatory - NCT00331851
LEAD 1 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgNA
LEAD 2 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgNA
LEAD 4 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgNA
Pratley (1.8 vs 1.2), 2010liraglutide 1.8mgliraglutide 1.2mgNA
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)364 (242/122) NCT00318461
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)348 (234/114) NCT00318422
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)347 (232/115) NCT00331851
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)355 (178/177) NCT00333151
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptin440 (221/219) Confirmatory NCT00700817
NN2211-1333liraglutide other dosesNA
Seino, 2010liraglutide other dosesglibenclamide411 (272/139) Confirmatory NCT00393718
Madsbad (vs Glimepiride), 2004liraglutide other dosesglimepiride161 (135/26) Exploratory
EAGLE ongoing liraglutide other dosesinsulin glargineNA NCT01117350
Feinglos, 2005liraglutide other dosesmetformin210 (176/34) Exploratory
Harder, 2004liraglutide other dosesplacebo33 (21/12) Exploratory
Kaku 0.6mg, 2010liraglutide other dosesplacebo176 (88/88)
LIBRA ongoing liraglutide other dosesplaceboNA NCT01270789
Madsbad (vs placebo), 2004liraglutide other dosesplacebo164 (135/29)
NCT00978393 ongoing liraglutide other dosesplaceboNA NCT00978393
NN2211-1571 (Vilsbøll), 2007liraglutide other dosesplacebo163 (123/40) Exploratory NCT00154401
NN2211-1799 ongoing liraglutide other dosesplaceboNA NCT00620282
NN2211-1800 ongoing liraglutide other dosesplaceboNA NCT00943501
NN2211-3619 ongoing liraglutide other dosesplaceboNA NCT01206101
NN8022-1922 ongoing liraglutide other dosesplaceboNA NCT01272232
NN8022-1923 ongoing liraglutide other dosesplaceboNA NCT00781937
Seino, 2008liraglutide other dosesplacebo226 (180/46) Exploratory NCT00154414
NCT01234649 ongoing liraglutide other dosesplacebo (add on MET)NA NCT01234649
NN2211-1796liraglutide other dosesplacebo (add on MET)NA NCT00614120
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU)NA NCT00395746
Kaku 0.9mg, 2010liraglutide other dosesplacebo (on top SU)176 (88/88)
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU)460 (228/232) Confirmatory NCT00318422
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET)NA NCT01296412

Obesity and overweight - All mechanism in all type of patients

Astrup (NN8022-1807 ), 2009liraglutideplaceboNA NCT00422058



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons